top of page

 

 

Gilteritinib is a medication used to treat a specific type of blood cancer called acute myeloid leukemia (AML). Let's break down what Gilteritinib is, how it works, and why it's used in simple terms.

Firstly, acute myeloid leukemia (AML) is a type of cancer that affects the blood and bone marrow, where blood cells are made. In AML, the bone marrow produces abnormal white blood cells called blasts, which grow quickly and crowd out healthy blood cells. Gilteritinib is a targeted therapy drug designed to specifically attack these abnormal cells.

Now, let's talk about how Gilteritinib works. Imagine the cancer cells as troublemakers in the bone marrow, disrupting the normal production of blood cells. Gilteritinib is like a superhero that targets and eliminates these troublemakers.

Gilteritinib works by blocking a protein called FLT3, which is found on the surface of most AML cells. FLT3 helps the leukemia cells grow and divide rapidly. By blocking FLT3, Gilteritinib slows down the growth of the leukemia cells and eventually kills them off, giving the body a chance to fight back.

One of the reasons doctors choose Gilteritinib for treating AML is because it's a targeted therapy, meaning it specifically targets the cancer cells while sparing healthy cells as much as possible. This can result in fewer side effects compared to traditional chemotherapy, which can affect both cancerous and healthy cells.

Gilteritinib is usually taken orally, in the form of tablets or capsules. The dosage and frequency of the medication depend on factors like the patient's overall health, the stage of AML, and how well they respond to the treatment.

However, like any medication, Gilteritinib isn't without risks. Some common side effects include nausea, diarrhea, fatigue, and low blood cell counts. These side effects can vary from person to person, and doctors will monitor patients closely to manage any issues that arise.

In summary, Gilteritinib is a targeted therapy drug used to treat acute myeloid leukemia by specifically targeting and destroying the abnormal cancer cells in the bone marrow. While it can be effective in treating AML, it's essential for patients to discuss potential benefits and risks with their doctors before starting treatment. Gilteritinib offers hope for patients battling AML and provides another weapon in the fight against cancer.

 

Have any queries, book a consultation with our Oncology Clinical Specialist

Gilteritinib

₹500.00Price
  • Imagine your body's bone marrow as a factory that makes blood cells. Sometimes, there's a glitch in the system, and certain cells called blasts start growing out of control, causing leukemia, like acute myeloid leukemia (AML).

    Gilteritinib comes in like a special agent. It has a target: a protein called FLT3 that's found on the surface of these leukemia cells. Once Gilteritinib finds its target, it blocks FLT3, which is like cutting off the fuel supply to the leukemia cells.

    Without FLT3, the leukemia cells can't grow and multiply as fast. Eventually, they stop growing altogether, and some of them may even die off. This slows down the progression of the leukemia and gives the body a chance to fight back against the cancer.

    In simple terms, Gilteritinib is like a lock that blocks the door for leukemia cells to keep spreading. It helps put the brakes on the cancer's growth, giving the body time to regain control.


    Have any queries, book a consultation with our Oncology Clinical Specialist

bottom of page